Data as of Apr 17
| +0.02 / +0.03%|
The 17 analysts offering 12-month price forecasts for Cubist Pharmaceuticals Inc have a median target of 80.00, with a high estimate of 97.00 and a low estimate of 60.00. The median estimate represents a +25.10% increase from the last price of 63.95.
The current consensus among 19 polled investment analysts is to Buy stock in Cubist Pharmaceuticals Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.